Molecular characteristics like ABC cell-of-origin, MCD phenotype, TP53 mutation, double hit, or CDKN2A deletion (del9p) combined with clinical parameters could help to stratify patients and rationalize the use of CNS prophylaxis. This evidence concerns the gene TP53 and aneurysmal bone cyst.